Tauro-alpha-muricholic acid | 25696-60-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Tauro-alpha-muricholic acid
• 英文别名: 2-[[(4R)-4-[(3R,5R,6S,7R,10R,13R,17R)-3,6,7-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonic acid
• CAS: 25696-60-0
• 化学式: C₂₆H₄₅NO₇S
• 分子量: 515.7
• InChiKey: XSOLDPYUICCHJX-OEYGYFRSSA-N

物化性质

• 密度：
  1.264±0.06 g/cm3(Predicted)
• 溶解度：
  DMSO（少许）、甲醇（少许）、水（少许）
• 物理描述：
  Solid
• 碰撞截面：
  209.4 Ų [M-H]- [CCS Type: DT, Method: single field calibrated]

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  35
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  153
• 氢给体数：
  5
• 氢受体数：
  7

文献信息

• [EN] BILE ACIDS AND USE IN DISEASE TREATMENT<br/>[FR] ACIDES BILIAIRES ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES
  申请人：UNIV CALIFORNIA

  公开号：WO2020154397A1

  公开（公告）日：2020-07-30

  Compositions and methods of use for modulating bile acids, including phenylalanocholic acid, tyrosocholic acid and leucocholic acid, to treat diseases, such as inflammatory bowel disease. In embodiments, the invention provides pharmaceutical compositions that modulate levels of a bile acid conjugate in a subject. In embodiments, the invention provides pharmaceutical compositions that modulate levels of a bile acid conjugate in a particular organ or bodily region of the subject.

  调节胆汁酸，包括苯丙氨胆酸、酪氨酸胆酸和亮氨酸胆酸等的使用组合物和方法，用于治疗炎症性肠病等疾病。在实施例中，本发明提供了调节受试者体内胆汁酸共轭物水平的药物组合物。在实施例中，本发明提供了调节受试者特定器官或身体区域内胆汁酸共轭物水平的药物组合物。
• BILE ACIDS AND USE IN DISEASE TREATMENT
  申请人：The Regents of the University of California

  公开号：EP3914273A1

  公开（公告）日：2021-12-01
• ENGINEERED COMMENSAL BACTERIA AND METHODS OF USE
  申请人：The Regents of the University of California

  公开号：US20200056145A1

  公开（公告）日：2020-02-20

  Provided are compositions comprising populations of commensal bacteria isolated from a microbiome sample of a mammalian subject and engineered to express a heterologous polynucleotide, compositions comprising such engineered commensal bacteria and methods of use for delivering a therapeutic polypeptide to a mammal, e.g, by administering the engineered commensal/native bacteria.
• METABOLIC BIOMARKERS FOR THE IDENTIFICATION AND CHARACTERIZATION OF ALZHEIMERS DISEASE
  申请人：UNIVERSITY OF HAWII CANCER CENTER

  公开号：US20210293794A1

  公开（公告）日：2021-09-23

  Embodiments of the present disclosure relate generally to the analysis of broad metabolic changes associated with neurological disorders. In particular, the present disclosure provides materials and methods relating to the use of metabolomics as a biochemical approach to identify peripheral metabolic changes and corresponding metabolic biomarkers of neurological disorders. Embodiments of the present disclosure include the use of bile acids and their derivatives as metabolic biomarkers to aid in the determination of whether a subject suffers from, or is at risk of developing, a neurological disorder, such as Alzheimer's Disease (AD).
• Bile Acids and Use in Disease Treatment
  申请人：The Regents of the University of California

  公开号：US20220202881A1

  公开（公告）日：2022-06-30

  Compositions and methods of use for modulating bile acids, including phenylalanocholic acid, tyrosocholic acid and leucocholic acid, to treat diseases, such as inflammatory bowel disease. In embodiments, the invention provides pharmaceutical compositions that modulate levels of a bile acid conjugate in a subject. In embodiments, the invention provides pharmaceutical compositions that modulate levels of a bile acid conjugate in a particular organ or bodily region of the subject.